Combination treatment therapies are common for those suffering from mesothelioma because the aggressive nature of this asbestos-caused disease makes it difficult to treat effectively. Ongoing developments and advancements in medicine have also helped mesothelioma patients extend their life and manage pain throughout the years. While there is no cure for[…]
Cisplatin (Platinol ®)
Phase III Clinical Trial for Nintedanib Discontinued After Yielding Negative Results
Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year –[…]
Survival Improves in Mesothelioma Patients who Received an Electricity-Based Treatment
The success of a recent Phase II clinical trial in malignant pleural mesothelioma has scientists and researchers excited about the possibility of adding a new treatment that will not only improve survival, but also improve quality of life of the cancer patient. Tumor Treating Fields, which is a therapy that[…]
Metal-based Compound May Reduce Tumor Size in Pleural, Peritoneal Mesothelioma
Mesothelial cells are found in the lining of major organs such as the chest or the abdomen. When asbestos fibers are inhaled or ingested, they slice through the soft tissue and become embedded in the lining of these organs. These fibers cause genetic mutations in the mesothelial cells which then[…]
Why is Chemotherapy Often Ineffective in Those Suffering from Mesothelioma?
Mesothelioma is a difficult cancer to treat for a multitude of reasons. A mesothelioma diagnosis is rare – only about 3,000 people per year in the United States are diagnosed – and this can make it difficult to study, given that there is generally a very small sample of patients[…]
ONCOS-102 Update: Mesothelioma Patients Responded after Phase II Clinical Trial
Advancement in mesothelioma treatments over the past decade has been relativity stagnant, according to Targovax – a Norwegian immune-cology company dedicated to the study and research of immunotherapy treatments. However, those suffering from mesothelioma have hope, as continuing phases of clinical trials are showing positive results; the latest being ONCOS-12,[…]
Aerosol Chemotherapy – Targeting Peritoneal Mesothelioma Through Pressurized Medicine
Peritoneal mesothelioma is an incredibly rare form of cancer that affects the peritoneum, or abdominal lining. It is not entirely understood how exposure to asbestos causes this type of cancer, but scientists and researchers theorize that ingested asbestos fibers work themselves into the peritoneal cavity, or if inhaled, are transported[…]
Effective Chemotherapy May Rest Upon Reducing Overactive Enzyme
Chemotherapy for mesothelioma patients has been notoriously difficult and the cancer continues to be overwhelmingly unresponsive to such treatment in many cases. However, researchers and scientists have been continually investigating new techniques that involve adjusting how chemotherapy reacts on a cellular level. A study published in the Frontiers in Pharmacology[…]
ONCOS-102 Passes Safety Evaluation in Phase I Clinical Trials, Phase II Clinical Trial Recommended
A new immunotherapy developed by Targovax has recently passed Phase I clinical trials and is set to begin Phase II evaluation of this new treatment that may help those suffering from mesothelioma. ONCOS-102 was used in separate Phase I clinical trials; one in combination with chemotherapy, and one with immunotherapy.[…]
Bevacizumab – A Positive Treatment with Serious Side Effects
Bevacizumab (Avastin) is commonly viewed as chemotherapy treatment because when administered intravenously, it is particularly effective in controlling such illnesses such as lung cancer and colon cancer. However, it is a bit different than traditional chemotherapy treatments, which directly attack cancer cells. Bevacizumab fights cancer cells by cutting off oxygen[…]
Skip to content